JW Life Science Corp
KRX:234080
Operating Margin
JW Life Science Corp
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
|
JW Life Science Corp
KRX:234080
|
197B KRW |
15%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
765.6B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
403.3B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
207.3B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
180.2B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
167.5B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
213.1B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
141B USD |
27%
|
JW Life Science Corp
Glance View
JW Life Science Corp. manufactures intravenous fluids. The company is headquartered in Dangjin, Chungcheongnam-Do. The company went IPO on 2016-10-27. The firm is engaged in manufacture of basic IV fluid including water, electrolytes and glucose; nutrient infusion solution including amino acids, lipids, proteins, vitamins and minerals; and special infusion solution, which is used in special cases. The firm is also engaged in manufacture of total parenteral nutrition (TPN) products and others.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on JW Life Science Corp's most recent financial statements, the company has Operating Margin of 15%.
You don't have any saved screeners yet